Barclays PLC increased its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 163.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 262,449 shares of the company's stock after purchasing an additional 163,005 shares during the quarter. Barclays PLC owned approximately 0.18% of MiMedx Group worth $1,550,000 as of its most recent SEC filing.
Other institutional investors also recently added to or reduced their stakes in the company. Paradigm Capital Management Inc. NY raised its holdings in MiMedx Group by 6.6% in the second quarter. Paradigm Capital Management Inc. NY now owns 4,167,200 shares of the company's stock worth $28,879,000 after purchasing an additional 258,700 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of MiMedx Group by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company's stock worth $16,518,000 after acquiring an additional 44,254 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in MiMedx Group by 6.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company's stock valued at $8,483,000 after acquiring an additional 92,726 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in MiMedx Group by 47.0% in the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company's stock valued at $8,958,000 after acquiring an additional 413,443 shares in the last quarter. Finally, Harbor Capital Advisors Inc. grew its holdings in MiMedx Group by 299.9% in the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company's stock worth $6,074,000 after purchasing an additional 770,744 shares during the last quarter. Institutional investors own 79.15% of the company's stock.
MiMedx Group Trading Down 2.3 %
Shares of MiMedx Group stock opened at $8.65 on Monday. The firm's 50 day simple moving average is $8.98 and its two-hundred day simple moving average is $7.33. The firm has a market capitalization of $1.27 billion, a price-to-earnings ratio of 15.73 and a beta of 1.96. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10.
Analyst Ratings Changes
Separately, StockNews.com cut MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, MiMedx Group currently has an average rating of "Buy" and an average price target of $12.00.
Get Our Latest Stock Analysis on MiMedx Group
About MiMedx Group
(
Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
See Also
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
